Bedrijfsupdate14 okt 2026ENValneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare ConferencesValneva SECompany newsroom
Bedrijfsupdate7 okt 2026ENValneva Provides Update on IXCHIQ® in the United KingdomValneva SECompany newsroom
Bedrijfsupdate14 aug 2026ENPfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines AgencyValneva SECompany newsroom
Bedrijfsupdate13 aug 2026ENValneva Reports Half Year 2026 Financial Results and Provides Corporate UpdatesValneva SECompany newsroom
Bedrijfsupdate22 jul 2026ENValneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026Valneva SECompany newsroom
Bedrijfsupdate25 jun 2026ENValneva Announces Successful Outcome of its Annual General MeetingValneva SECompany newsroom
Bedrijfsupdate4 jun 2026ENValneva Announces Availability of Documentation for its Annual General MeetingValneva SECompany newsroom
Bedrijfsupdate28 mei 2026ENValneva to Participate at U.S. and European Investor Conferences in JuneValneva SECompany newsroom
Bedrijfsupdate13 mei 2026ENValneva Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesValneva SECompany newsroom
Bedrijfsupdate5 mei 2026ENValneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026Valneva SECompany newsroom
Bedrijfsupdate30 apr 2026ENValneva Announces the Successful Completion of an €84 million Reserved OfferingValneva SECompany newsroom
Bedrijfsupdate26 mrt 2026ENValneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DCValneva SECompany newsroom
